🔗 Visit the ClinicalTrials.gov page for NCT00734877
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. | Haematologica | 2012 | 1.53 |
| 2 | Trial watch: Chemotherapy with immunogenic cell death inducers. | Oncoimmunology | 2012 | 1.33 |
| 3 | Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. | Nat Commun | 2016 | 0.88 |
| 4 | Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. | Blood | 2015 | 0.86 |
| 5 | Genetic factors influencing the risk of multiple myeloma bone disease. | Leukemia | 2015 | 0.75 |